Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-Cell lymphoma
Conclusion: Total healthcare costs increased with each additional LoT in the R/R DLBCL setting. Further improvements of first-line treatments that reduce the need for subsequent LoTs would potentially lessen the economic burden of DLBCL.PMID:38686393 | DOI:10.1080/13696998.2024.2349472 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 30, 2024 Category: Health Management Authors: Justin Gatwood Anthony Masaquel David Fox Daniel Sheinson Cameron James Jia Li Farah Hossain Ryan Ross Source Type: research
Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening
Conclusions: Triennial screening with mt-sDNA resulted in better clinical outcomes at a lower cost compared with the modeled blood-based test even at perfect adherence, supporting application of blood-based tests only as a secondary screening option.PMID:38686394 | DOI:10.1080/13696998.2024.2349467 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 30, 2024 Category: Health Management Authors: John B Kisiel A Mark Fendrick Derek W Ebner A Burak Ozbay Vahab Vahdat Chris Estes Paul J Limburg Source Type: research
A comparison of healthcare utilization and outcomes following skin vs. serum-specific IgE allergy testing
Conclusions: Allergy testing, regardless of the testing method used, is associated with decreases in ED and UR visits at 1-year follow-up. sIgE allergy testing is associated with lower testing cost and fewer allergist/immunologist visits, compared to skin testing.PMID:38682798 | DOI:10.1080/13696998.2024.2349471 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 29, 2024 Category: Health Management Authors: Yang Z Lu Kenny Yat-Choi Kwong Source Type: research
Cost-effectiveness analysis of transcatheter aortic valve implantation in aortic stenosis patients at low- and intermediate-surgical risk in Japan
CONCLUSIONS: TAVI was dominant and cost-effective compared to SAVR in intermediate- and low-risk patients, respectively. These results suggest that TAVI can provide meaningful value to Japanese patients relative to SAVR, at a reasonable incremental cost for patients at low surgical risk and potentially resulting in cost-savings in patients at intermediate surgical risk.PMID:38654415 | DOI:10.1080/13696998.2024.2346397 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 24, 2024 Category: Health Management Authors: Junjiro Kobayashi Suzanne J Baron Kensuke Takagi Christin A Thompson Xiayu Jiao Kaoru Yamabe Source Type: research
Economic and healthcare resource utilization assessments of pet imaging in coronary artery disease diagnosis: a systematic review and discussion of opportunities for future economic evaluations
Conclusions: This SLR identified economic and HCRU evaluations following PET- and SPECT-MPI for CAD diagnosis and determined that existing studies do not capture all pertinent outcome parameters or link diagnostic performance to downstream HCRU and cardiac outcomes, thus, resulting in simplified assessments of CAD burden. A limitation of this work relates to heterogeneity in study designs, patient populations, and follow-up times of existing studies. Resultingly, it was challenging to pool data in meta-analyses. Overall, this work provides a foundation for the development of comprehensive economic models for PET- and SPECT...
Source: Journal of Medical Economics - April 23, 2024 Category: Health Management Authors: Nicole Ferko Stacey Priest Lamees Almuallem Alicyia Walczyk Mooradally Di Wang Abril Oliva Ramirez Erika Szabo Arturo Cabra Source Type: research
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland
Conclusions remained unchanged in most scenarios. Results' drivers included BASDAI50 response rate and disease management cost.CONCLUSION: The bimekizumab treatment-pathway represents a cost-effective option across the axSpA disease spectrum in Scotland. Bimekizumab is cost-effective compared to a secukinumab-pathway that includes dose up-titration, and has similar costs and QALYs to an ixekizumab-pathway.PMID:38650583 | DOI:10.1080/13696998.2024.2342209 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 23, 2024 Category: Health Management Authors: Michael F M ørup Vanessa Taieb Damon Willems Micah Rose Nikos Lyris Mark Lamotte Laetitia Gerlier Howard Thom Source Type: research
Value-based payment and financing for cell and gene therapies: challenges and potential solutions
J Med Econ. 2024 Apr 23:1-6. doi: 10.1080/13696998.2024.2346406. Online ahead of print.NO ABSTRACTPMID:38652008 | DOI:10.1080/13696998.2024.2346406 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 23, 2024 Category: Health Management Authors: James X Zhang Lisa R Shugarman Source Type: research
Impact of < em > pseudomonas aeruginosa < /em > on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis
Conclusion Exacerbated NCFB with PA+ was associated with increased antibiotic usage, greater resource utilization, and increased costs. The major contributor to the cost differences was the use of inpatient services. Treatment strategies aimed at reducing the need for inpatient treatment could lessen the disparities observed in patients with NCFB.PMID:38646702 | DOI:10.1080/13696998.2024.2340382 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 22, 2024 Category: Health Management Authors: Meg Franklin Michael E Minshall Federica Pontenani Sunjay Devarajan Source Type: research
The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs
CONCLUSIONS: There is a high disease burden of HPV-related cancer-related deaths in the CEE region, with a large economic impact to society due to substantial productivity losses. It is critical to implement and reinforce public health measures with the aim to reduce the incidence of HPV-related diseases, and the subsequent premature cancer deaths. Improving HPV screening and increasing vaccination programs, in both male and female populations, could help reduce this burden.PMID:38638098 | DOI:10.1080/13696998.2024.2341572 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 19, 2024 Category: Health Management Authors: Ugne Sabale Eugenia Karamousouli Lazar Popovic Zo árd Tibor Krasznai Daniel Harrop Anne Meiwald Robert Hughes Georgie Weston Goran Bencina Source Type: research
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data
CONCLUSIONS: The study shows that mUC is associated with significant HCRU and costs across different types of 1 L systemic therapy.PMID:38639988 | DOI:10.1080/13696998.2024.2331893 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 19, 2024 Category: Health Management Authors: G ünter Niegisch Marc-Oliver Grimm Fraence Hardtstock Julia Krieger Alexandra Starry Ulrike Osowski Barthold Deiters Ulf Maywald Thomas Wilke Mairead Kearney Source Type: research
The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs
CONCLUSIONS: There is a high disease burden of HPV-related cancer-related deaths in the CEE region, with a large economic impact to society due to substantial productivity losses. It is critical to implement and reinforce public health measures with the aim to reduce the incidence of HPV-related diseases, and the subsequent premature cancer deaths. Improving HPV screening and increasing vaccination programs, in both male and female populations, could help reduce this burden.PMID:38638098 | DOI:10.1080/13696998.2024.2341572 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 19, 2024 Category: Health Management Authors: Ugne Sabale Eugenia Karamousouli Lazar Popovic Zo árd Tibor Krasznai Daniel Harrop Anne Meiwald Robert Hughes Georgie Weston Goran Bencina Source Type: research
